Table 1 Baseline patient and tumor characteristics
N = 180 | Mean ± SD | Patients | n (%) | |
|---|---|---|---|---|
Age (years) | 59.4 ± 12.2 | |||
Gender | Women | 82 | (45.6) | |
Men | 98 | (54.4) | ||
Smoking History | Positive | 103 | (57.3) | |
Negative | 77 | (42.7) | ||
Wood-smoke exposure | Positive | 73 | (40.6) | |
Negative | 103 | (59.4) | ||
ECOG | 0 | 38 | 21.1) | |
1 | 115 | (63.9) | ||
2 | 26 | (14.4) | ||
3 | 1 | (0.6) | ||
Clinical Stage | III | 28 | (15.6) | |
IV | 152 | (84.4) | ||
Histology | Adenocarcinoma | 152 | (84.4) | |
Squamous-cell | 14 | (7.8) | ||
Undifferentiated | 13 | (7.2) | ||
Large-cell carcinoma | 1 | (0.6) | ||
Baseline CEA | 242.8 ± 685 | |||
Treatment | Platinum-Based CT | 168 | (93.3) | |
Tyrosine-kinase | ||||
inhibitors | 12 | (6.7) | ||
Tumor ResponseEvaluation | Complete/Partial | 51 | (28.3) | |
Stable Disease | 89 | (49.4) | ||
Progressive Disease | 40 | (22.2) |